博雅生物: 监事会决议公告

Core Viewpoint - The supervisory board of China Resources Boya Bio-Pharmaceutical Group Co., Ltd. confirmed the legality and compliance of the company's 2025 semi-annual report and related proposals, ensuring no misleading statements or omissions [1][2][3]. Group 1: Supervisory Board Meeting - The 12th meeting of the 8th supervisory board was held on August 21, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1]. - The supervisory board approved the procedures for reviewing the 2025 semi-annual report, affirming its authenticity and completeness [1][2]. Group 2: Profit Distribution Proposal - The supervisory board agreed that the profit distribution proposal for the 2025 semi-annual report complies with regulatory guidelines and the company's profit distribution policy [2]. - The proposal will be submitted for review at the company's first extraordinary general meeting of 2025 [2]. Group 3: Fund Management - The supervisory board expressed approval of the management of the special account for raised funds, confirming compliance with relevant regulations [2][3]. - The report on the storage and use of raised funds for the first half of 2025 was deemed accurate and complete by the supervisory board [2][3]. Group 4: Use of Bank Acceptance Bills - The supervisory board approved the proposal to use bank acceptance bills to pay for project funding and to replace the funds with raised capital [3].